CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Focal therapy for localized prostate cancer — Coverage Criteria

This policy governs coverage and coding for focal therapies (e.g., focal laser ablation, HIFU, cryoablation, radiofrequency ablation, photodynamic therapy) used to treat localized prostate cancer for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyFocal therapy for localized prostate cancer — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 10, 2015

Next Review DateN/A

Key ActionVerify member eligibility and benefit coverage prior to providing focal therapy services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredBlueCHiP for Medicare stance

Not medically necessaryCommercial products stance

55899Coding note

C9747HIFU HCPCS

Insufficient evidenceRationale

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Coverage Determination

Covered when ALL of the following are met:

Medicare Coverage: Use of any focal therapy modality to treat patients with localized prostate cancer is not covered by BlueCHiP for Medicare because the evidence is insufficient to determine effects on health outcomes.

Commercial Coverage: Use of any focal therapy modality to treat patients with localized prostate cancer is not medically necessary for Commercial Products because the evidence is insufficient to determine effects on health outcomes.

HCPCS code C9747 ("Ablation of prostate, transrectal, high intensity focused ultrasound (HIFU), including imaging guidance") is explicitly identified in this policy as not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products. When reporting focal prostate procedures, there is no specific CPT; use unlisted CPT code 55899 for claims submission.

Member-specific subscriber agreements, member certificates, and employer agreements take precedence over this medical policy. Providers should verify the member's benefits and eligibility through the provider call center prior to delivering focal therapy; if services are determined to be not medically necessary or non-covered benefits, the provider may not bill the member unless the member has been informed and has agreed in advance to accept financial responsibility.

For Commercial Products, the use of any focal therapy modality to treat localized prostate cancer is considered not medically necessary because the available evidence is insufficient to determine the effects of these technologies on health outcomes.

Provider Requirements and Billing Risks

Prior Authorization

Not applicable

Note

Benefit Verification

Verify member eligibility and benefits prior to scheduling or performing focal therapy. Coverage varies by product and subscriber/employer agreements; benefits and eligibility are determined by the member's benefit booklet, subscriber agreement, or employer contract.

Contact the provider call center for member-specific benefit information.
For services determined not medically necessary or non-covered, providers may not charge the member unless the member is informed and agrees in advance to pay.
BlueCHiP for Medicare and Commercial Product benefits may differ — always confirm plan-specific coverage.

Note

Benefits and Coverage

Benefits may vary between groups and contracts. Refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable coverage determinations.

Provider call center is the operational contact for benefit questions.

Billing Rule

Coding and Documentation

Use unlisted CPT 55899 for this procedure. HCPCS code C9747 is not covered for BlueCHiP for Medicare and is considered not medically necessary for Commercial Products.

55899 — Unlisted procedure, male genital system (use for focal prostate ablation procedures).
C9747 — Ablation of prostate, transrectal, HIFU (not covered for BlueCHiP for Medicare; not medically necessary for Commercial Products).

Denial Risk

Financial / Coverage Risk Note

If a service is determined to be not medically necessary or non-covered by the member's plan, the provider may be at financial risk. Providers may not bill or collect payment from the member unless the member has been informed and has agreed in advance to accept financial responsibility. Refer to your participation agreement for applicable provisions.

Provider should obtain and document member acknowledgement if member will self-pay for non-covered services.
Subscriber/employer agreements govern final benefit determination and supersede this policy.

Clinical Background

Focal therapy for localized prostate cancer targets the dominant or index lesion with the goal of reducing tumor burden while preserving urinary, sexual, and rectal function compared with whole-gland treatments. Accurate lesion identification (for example, with multiparametric MRI (mp‑MRI) and, when indicated, transperineal template mapping) and careful patient selection are critical. The clinical evidence base is limited—composed mainly of case series and noncomparative studies with heterogeneous methods and short follow-up—so long‑term effects on disease control and functional outcomes remain uncertain.

Key Definitions

Index lesion — definition and clinical role

Clinical roleTarget for focal therapy: focal treatment strategies aim to ablate the index lesion while sparing surrounding tissue to preserve urinary, sexual, and rectal function.

Oncologic rationalePathologic and molecular evidence suggests a single index tumor focus is usually responsible for disease progression and metastasis, supporting lesion-targeted approaches.

Impact on treatment selectionAccurate identification of the index lesion is critical to focal therapy success and determines whether lesion-targeted or more extensive hemi/subtotal approaches are appropriate.

TPM — transperineal template prostate mapping definition and notes

DefinitionTransperineal template prostate mapping (TPM) is a systematic, template-guided transperineal biopsy technique that provides 3-dimensional coordinates of cancerous lesions and is considered a reference standard for disease localization for focal therapy.

Performance and roleTPM has accuracy rates of approximately 87% to 95% for detecting clinically significant cancer and is recommended by guideline bodies as a reference standard for lesion localization.

Practical considerationsTPM is resource-intensive, typically requires general anesthesia, multiple biopsy cores and specimen processing, and is associated with complications such as urinary retention (~6%), prostatitis (~4%), and perineal hematoma/bruising/pain (~5%).

mp-MRI — multiparametric MRI definition and components

DefinitionMultiparametric magnetic resonance imaging (mp-MRI) is prostate MRI typically including T1, T2, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging used to detect and risk-stratify prostate cancer lesions.

Diagnostic performanceAgainst TPM as the reference, mp-MRI sensitivity for clinically significant lesions ranges roughly 58% to 73% with negative predictive value of about 84% to 89%, and specificity around 71% to 84%.

Clinical role and limitationsmp-MRI can detect and risk-stratify high-grade, larger foci and may be sufficient to rule out clinically significant cancer in some settings, but suspicious lesions still require histologic confirmation; mp-MRI interpretation and in‑scanner biopsy require specialized equipment and experienced uroradiologists.

Focal therapy — definition and example modalities

DefinitionFocal therapy refers to targeted ablation of prostate cancer lesions intended to treat localized disease while sparing surrounding normal tissue to reduce morbidity compared with whole‑gland treatments.

Example modalitiesModalities cited include cryoablation, high‑intensity focused ultrasound (HIFU), focal laser ablation (FLA), radiofrequency ablation, and vascular‑targeted phototherapy.

Intended benefitAims to ablate the index lesion or regionally confined disease to reduce tumor burden while preserving urinary, sexual, and rectal function and leaving options for subsequent definitive therapy if needed.

Evidence contextEvidence consists largely of case series and noncomparative studies with short follow‑up; randomized data are limited but include at least one trial of partial gland ablation versus active surveillance.

OpenPayer

Focal therapy for localized prostate cancer — Coverage Criteria

Coverage Determinations

Coding and Billing

Provider Requirements and Billing Risks

Clinical Background

Key Definitions